Infectious diseases

#Collaboration #Evotec #France #Infectious diseases #Pfizer

Evotec and Pfizer collaborate on metabolic and infectious diseases

Evotec and Pfizer have entered into a multi-year research collaboration, initially focused on early discovery research for metabolic and infectious diseases. The research will be carried out at Evotec’s sites in France, including Campus Curie in Toulouse with capabilities spanning high throughput screening, in vitro and in vivo biology, proteomics… Read More

#Business & Investment #News

#Career #Infectious diseases #Interview #Kling Biotherapeutics #Meet the Researcher

Meet the researcher: Stefano Gullà, Kling Biotherapeutics

DDW’s Megan Thomas speaks to Stefano Gullà, Chief Scientific Officer at Kling Biotherapeutics.   MT: Where do you work, and can you tell us what you’re working on at the moment?  SG: I am the Chief Scientific Officer at Kling Biotherapeutics. Together with my colleagues, I am tackling what is… Read More

#Cancer Research #Exclusive Content

Scientific technology
#AI / data analytics / healthtech / informatics #Clinical development #Data automation #Data management #Diagnostics #Drug discovery #Electronic Lab Notebooks (ELN) #FAIR Principles #Genomics #Immunology / Virology & Vaccines #Infectious diseases #Informatics #mRNA #Personalised medicine #Precision medicine #Predictive diagnostics #Public health

New podcast: Revolutionary technology for drug discovery

This is the latest episode of the free DDW narrated podcast, titled “Revolutionary technology for drug discovery and development” which covers three written for Volume 23 – Issue 4, Fall 2022 of DDW. They are called: mRNA technology may hold the future for a cytomegalovirus vaccine; … Read More

#News

Antibodies
#Antibodies #Collaboration #Funding #Infectious diseases #LifeArc #Liverpool School of Tropical Medicine

Infectious diseases research fund will progress antibody therapies

Liverpool School of Tropical Medicine (LSTM) and LifeArc are partnering to launch a new Translational Development Fund to help tackle infectious diseases. LifeArc will invest £2.7 ($3.4) million into the fund, which will support the progression of new technologies and treatments for emerging viral threats and… Read More

#News

#ABL Diagnostics #Collaboration #Cytomegalovirus #Diagnostics #HIV #Human Papillomavirus #Infectious diseases #Laboratory #Microbiology #Roche #Tuberculosis #Viral hepatitis

Roche and ABL Diagnostics expand to South African laboratories  

Roche Diagnostics and ABL Diagnostics have launched a distribution partnership which will see Roche supplying ABLD products to South African laboratories.   Roche now has exclusive rights to distribute products, including the ABL DeepChek assays to laboratories implementing microbiology applications. These applications include HIV, Tuberculosis, Cytomegalovirus, Viral… Read More

#News

#Biopharmaceuticals #Biotechnology #Epidemiology #Infectious diseases #Novel candidates

Destiny Pharma publishes landmark XF-73 clinical data  

Destiny Pharma, a UK-based clinical stage biotechnology company focused on the development of novel medicines to prevent life threatening infections, has published landmark XF-73 clinical data in the US peer reviewed journal Infection Control & Hospital Epidemiology.    The paper was published by Dr. Julie Mangino… Read More

#News

Influenza
#Acute inflammatory conditions #Biopharmaceuticals #Human trials #Immunomodulators #Infectious diseases #Influenza

New results for severe influenza and inflammatory conditions 

Poolbeg Pharma, an infectious disease-focused biopharmaceutical company, has announced data from the bacterial lipopolysaccharide (‘LPS’) human challenge trial for POLB 001, a viral strain agnostic, small molecule immunomodulator being developed to address the unmet medical need arising from severe influenza and other acute inflammatory conditions.   POLB 001… Read More

#News

Outbreak map of the world
#Covid-19 #Global.health #Infectious diseases #Monkeypox #Outbreak #Pandemic #Pandemic prevention #Pandemic response

Pandemic data platform will model emerging infectious diseases

The Rockefeller Foundation will provide $3 million in new funding for Global.health (G.h) – an open-source platform for scientific pandemic data.  The investment will allow the platform to expand its international partnerships and modernise the global effort around coordinated pandemic prevention, surveillance, and response. Co-developed by researchers and engineers… Read More

#Covid-19 #News

#Clinical development #Immunology / Virology & Vaccines #Infectious diseases #mRNA #Public health

mRNA technology may hold the future for a cytomegalovirus vaccine 

Listen to this article on the DDW podcast: Allison August, M.D., Vice President, Clinical Development, Infectious Diseases at Moderna examines the data on cytomegalovirus (CMV), why attempts at vaccines for CMV have so far proved elusive and the emerging options to address this unmet need.  Although cytomegalovirus (CMV) is almost… Read More

#Exclusive Content #Trends & Analysis

#Covid-19 #Immunology / Virology & Vaccines #Infectious diseases #WHO

WHO updates Covid-19 strategy to reach unvaccinated  

The World Health Organisation (WHO) has released an update to its ongoing global Covid-19 strategy in order to reach individuals yet to be vaccinated.   The update to WHO’s Global Covid-19 Vaccination Strategy1, was made in response to the spread of Omicron subvariants, advances in vaccine evidence, and… Read More

#News

#Covid-19 #DNA #Drug discovery #Genomics #Infectious diseases

This week in drug discovery (18 -22 July)

News round-up by DDW’s Reece Armstrong for 18 – 22 July Covid-19 vaccines remain effective six months after second dose  Two doses of Covid-19 vaccines were sufficient in providing protection against severe cases of the infectious disease, according to new research.   New combination therapy… Read More

#News

#iiCON: Infection Innovation Consortium #Infectious diseases

Infectious disease centre reaches major milestone  

A major milestone has been met in the construction of a new multi-million-pound health centre in Liverpool.  The new Pembroke House centre will be operated jointly by Liverpool School of Tropical Medicine and iiCON: Infection Innovation Consortium. It aims to expand Liverpool’s leading capabilities in infectious disease… Read More

#News

#Immunology / Virology & Vaccines #Infectious diseases #Monkeypox

SIGA’s monkeypox treatment gets UK approval  

Pharmaceutical company SIGA Technologies has announced that its oral therapy tecovirimat has been approved in the UK for the treatment of smallpox, monkeypox, cowpox.  The therapy has also been approved for the treatment of complications following vaccination against smallpox in adults and children with a body weight… Read More

#News

Flu vaccine
#Flu vaccine #Infectious diseases #National Institutes of Health (NIH)

US launches trial for potential universal flu vaccine

The National Institutes of Health (NIH) has launched a Phase I clinical trial for a potential universal flu vaccine.   The trial will assess the vaccine candidate BPL-1357 which has been developed by researchers at the National Institute of Allergy and Infectious Diseases (NIAID). The candidate is a… Read More

#News

#Covid-19 #GSK #Infectious diseases #Vaccines

GSK invests into infectious disease research for low-income countries  

GSK is to invest £1 billion over the course of 10 years into research on infectious diseases that largely affect low-income countries.   In particular, the pharmaceutical company will aim to develop new vaccines and medicines that prevent and treat malaria, tuberculosis, HIV (through ViiV Healthcare), neglected tropical… Read More

#News

#Clinical trials #Infectious diseases #Malaria

Landmark approval of child-friendly malaria treatment 

According to the Medicines for Malaria Venture (MMV),the Australian Therapeutic Goods Administration (TGA) has approved the use of single-dose Kozenis (tafenoquine) in children aged two years and above in combination with chloroquine for the radical cure (prevention of relapse) of Plasmodium vivax (P. vivax) malaria.  The approval… Read More

#News #Trending News